睿知中国医院研究地图
候选清单

正在招募肝豆状核变性早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)

ClinicalTrials.gov 上登记的一项肝豆状核变性开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心安徽医科大学第一附属医院First Affiliated Hospital of Anhui Medical University合肥医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07240896,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Patinets with Wilson's disease confirmed by laboratory tests to have double-chromosome mutations in the ATP7B gene.

    入选标准第 3 条

  3. Other liver-related diseases and clinical symptoms that can cause liver injury, such as acute and chronic hepatitis, alcoholic liver disease, autoimmune liver disease, drug-induced liver injury, liver cirrhosis, liver ascites, esophageal varices, hepatic encephalopathy, hepatorenal syndrome, liver failure, liver malignancy, etc.; Subjects with Model for end-stage liver disease score (MELD)>13.

    排除标准第 4 条

  4. The subjects are atable patients with WD who have been trasted for at least six months without drug or dose changes for at least 6 momths at the time of screening , and have continuously used standard treatments [SOC, such as D-penicillamine, sodiu dihydroxypropane sulfonate, dimercaptosuccinic acid, trientine, and zinc preparations (zinc acetate, zinc gluconate, zinc sulfate)] for at least 6 months screening, and allowed subjects to continue with their prior SOC treatment.

    入选标准第 6 条

  5. ALT < 2 times of upper limit of normal value (ULN);

    入选标准第 10 条

    Hemoglobin < 90 g/L;

    排除标准第 8 条

    Creatinine clearance ≤30 mL/min, or glomerular filtration rate <45 mL/min/1.73 m²;

    排除标准第 9 条

    TBil≥2×ULN,ALP/TBil<4,AST/ALT>2.2;

    排除标准第 10 条

    Platelets < 70 ×10\^9/L;

    排除标准第 11 条

    Neutrophils < 1.0 × 10\^9 /L.

    排除标准第 12 条

  6. Pregnant women or lactating women.

    排除标准第 17 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07240896,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥18 years old, gender not limited.
  2. Meet the diagnostic criteria f Wilson's Disease in "Guidelines for Diagnosis and Treatment of Wilson's Disease (2022 Edition)", with a Leipzig score ≥4, at least one year between diagnosis and screening; ceruloplasmin level <0.1g/L.
  3. Patinets with Wilson's disease confirmed by laboratory tests to have double-chromosome mutations in the ATP7B gene.
  4. Low copper diet for at least six months befoer screening and willing to continue low copper diet during study.
  5. Fertile subjects agreed to adopt reliable contrraceptive methods from the screening until 6 months after the last administration.
  6. The subjects are atable patients with WD who have been trasted for at least six months without drug or dose changes for at least 6 momths at the time of screening , and have continuously used standard treatments [SOC, such as D-penicillamine, sodiu dihydroxypropane sulfonate, dimercaptosuccinic acid, trientine, and zinc preparations (zinc acetate, zinc gluconate, zinc sulfate)] for at least 6 months screening, and allowed subjects to continue with their prior SOC treatment.
  7. The subject's condition was fully controlled after treatment, and its definition must meet all of the following conditions:
  8. Serum NCC level ≥ 25 μg/L and ≤ 150 μg/L;
  9. Urinary copper ≥100 μg/24 hours and ≤900 μg/24 hours;;
  10. ALT < 2 times of upper limit of normal value (ULN);
  11. The investigator believes that no other laboratory values or clinical symptoms would stop current standard therapy;
  12. Subjects with good compliance, who can understand and cooperate to complete the requirements of protocol.
  13. The subjects voluntarily participated in the trial and signed the informed consent form.

排除标准:Exclusion Criteria:

  1. Allergy or intolerance to the investigational drug.
  2. Wilson's disease is accompanied by severe complications such as neurological and mental disorders.
  3. History of liver transplantation.
  4. Other liver-related diseases and clinical symptoms that can cause liver injury, such as acute and chronic hepatitis, alcoholic liver disease, autoimmune liver disease, drug-induced liver injury, liver cirrhosis, liver ascites, esophageal varices, hepatic encephalopathy, hepatorenal syndrome, liver failure, liver malignancy, etc.; Subjects with Model for end-stage liver disease score (MELD)>13.
  5. Other diseases that can cause hemolysis or anemia, such as erythrocytosis, Mediterranean anemia, hemolytic anemia, various causes of infection, large area burns, etc.
  6. Other diseases that can cause dysfunction of the nervous system, such as Parkinson's disease, Parkinson syndrome, various causes of dystonia, chorea, primary tremor, epilepsy, mental abnormalities (such as history of schizophrenia or suicide attempts), etc.
  7. Screening period laboratory examination indicators:
  8. Hemoglobin < 90 g/L;
  9. Creatinine clearance ≤30 mL/min, or glomerular filtration rate <45 mL/min/1.73 m²;
  10. TBil≥2×ULN,ALP/TBil<4,AST/ALT>2.2;
  11. Platelets < 70 ×10\^9/L;
  12. Neutrophils < 1.0 × 10\^9 /L.
  13. History of gastrointestinal bleeding within six months before screening.
  14. Subjects with history of moderate to severe depression, suicidal thoughts or behaviors and serious psychiatric within 6 months prior to screening.
  15. Subjects who have uncontrolled diseases of thr heart, liver, kidneys, endocrine system, digestive tract, metabolism, blood, or malignant tumors.
  16. Active hepatitis B virus infection or active hepatitis C virus infection, or human immunodeficiency virus antibody positive.
  17. Pregnant women or lactating women.
  18. Subjects who have participated other clinical trial within 3 months prior to screening or plan to participate during the clinical trial.
  19. Investigators evaluate other subjects who are not suitable to participate in this clinical trial.

引自 ClinicalTrials.gov, NCT07240896, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07240896,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07240896